Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of Microdose Latanoprost via Optejet
NCT03480906Completed
- Sponsor
- Hyperion DeFi
- Start
- Mar 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-blind trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in ocular hypertension and Glaucoma (2 arms), sponsored by Hyperion DeFi. Primary endpoint: Successful microtherapeutic administration to the ocular surface at Day 3. Started Mar 2018; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
ocular hypertensionGlaucoma
Beyond the preview
Go deeper on NCT03480906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480906.